[go: up one dir, main page]

MX2010006995A - 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use. - Google Patents

5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.

Info

Publication number
MX2010006995A
MX2010006995A MX2010006995A MX2010006995A MX2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A
Authority
MX
Mexico
Prior art keywords
phenyl
substituted
oxadiazolones
medical use
oxadiazolone
Prior art date
Application number
MX2010006995A
Other languages
Spanish (es)
Inventor
David Alexander Learmonth
Laszlo Erno Kiss
Humberto Dos Santos Ferreira
Patricio Manuel Vieira Araujo Soares Da Silva
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2010006995A publication Critical patent/MX2010006995A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)

Abstract

The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I).
MX2010006995A 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use. MX2010006995A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US930207P 2007-12-27 2007-12-27
PCT/PT2008/000054 WO2009084970A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Publications (1)

Publication Number Publication Date
MX2010006995A true MX2010006995A (en) 2010-08-18

Family

ID=40361548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006995A MX2010006995A (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.

Country Status (14)

Country Link
EP (1) EP2238131A1 (en)
JP (1) JP2011507952A (en)
KR (1) KR20100111691A (en)
CN (1) CN101959881A (en)
AR (1) AR069970A1 (en)
AU (1) AU2008344032A1 (en)
BR (1) BRPI0821482A2 (en)
CA (1) CA2710743A1 (en)
CL (1) CL2008003895A1 (en)
IL (1) IL206419A0 (en)
MX (1) MX2010006995A (en)
TW (1) TW200932732A (en)
WO (1) WO2009084970A1 (en)
ZA (1) ZA201005306B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074587A2 (en) * 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
AR076687A1 (en) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc ISOXAZOLINS AS INHIBITORS OF THE AMIDAHIDROLASA OF FATTY ACIDS AND PHARMACEUTICAL COM-POSITIONS CONTAINING THEM
WO2010151160A1 (en) * 2009-06-24 2010-12-29 Bial - Portela & Ca., S.A. O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931843A1 (en) * 1989-09-23 1991-04-04 Bayer Ag SUBSTITUTED 1,3,4-OXA (THIA) DIAZOLINONE PROCESS FOR THEIR PREPARATION AND THEIR USE OF THE CONTROL OF ENDOPARASITES
DE19942354A1 (en) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, their manufacture and use in medicinal products
WO2003043997A1 (en) * 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10208987A1 (en) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxy-1,3,4-oxidiazol-2-ones, their preparation and use in drugs
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-keto-oxazoles as modulators of fatty acid amide hydrolase

Also Published As

Publication number Publication date
EP2238131A1 (en) 2010-10-13
AR069970A1 (en) 2010-03-03
TW200932732A (en) 2009-08-01
AU2008344032A8 (en) 2010-08-19
CL2008003895A1 (en) 2010-06-25
CN101959881A (en) 2011-01-26
ZA201005306B (en) 2011-04-28
WO2009084970A1 (en) 2009-07-09
BRPI0821482A2 (en) 2015-07-14
CA2710743A1 (en) 2009-07-09
IL206419A0 (en) 2010-12-30
JP2011507952A (en) 2011-03-10
AU2008344032A1 (en) 2009-07-09
KR20100111691A (en) 2010-10-15

Similar Documents

Publication Publication Date Title
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
UA105229C2 (en) Pharmaceutical formulation
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
TN2009000509A1 (en) Pyrazole carboxylic acid amides useful as microbiocides
MX2009008099A (en) Compounds for the prevention and treatment of cardiovascular diseases.
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
MY151295A (en) Pyrimidyl indoline compound
EP2196220A4 (en) REMEDIES AGAINST HOST GRAFT REACTION COMPRISING AN INHIBITOR OF INTERLEUKIN-6 RECEPTORS AS AN ACTIVE INGREDIENT
TW200728307A (en) Novel spirochromanone derivatives
TW200626068A (en) Active compounds for seed treatment
UA102817C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR AGOMELATINE SYNTHESIS
MX2012003982A (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions.
IL193252A0 (en) N-hydroxyacrylamide compounds
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
TW200833657A (en) Novel process
MX2011011776A (en) Triptolide prodrugs.
UA102220C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR THE SYNTHESIS OF AGOMELATINE
WO2010005572A3 (en) Alpha-keto heterocycles as faah inhibitors
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
TN2011000355A1 (en) Novel microbiocides
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
MX2010010877A (en) Compounds and compositions as itpkb inhibitors.
MX2010006995A (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2009140101A3 (en) Imidazopyridine compounds useful as mmp-13 inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal